New Potomac Partners’s Allergan plc AGN Stock Holding History

New Potomac Partners’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,943	Closed	-$645K	–	154
2017 Q4	$645K	Buy	+3,943	New	+$708K	0.62%	52

Other funds holding AGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

New Potomac Partners's AGN Position: Q1 2018 in Review

New Potomac Partners sold out of Allergan plc (AGN) in Q1 2018, closing a stake of 3,943 shares — an estimated $645K sold.

New Potomac Partners first reported a position in AGN in Q4 2017 and held it in 1 quarter. The position peaked at $645K in Q4 2017. 1,022 funds tracked by Wall St. Rank hold AGN as of Q1 2018.

New Potomac Partners reported no remaining Allergan plc position as of Q1 2018 after selling out during the quarter.
New Potomac Partners sold 3,943 Allergan plc shares in Q1 2018, an estimated $645K.
New Potomac Partners first reported a position in Allergan plc in Q4 2017 and held it in 1 quarter.
New Potomac Partners's Allergan plc position peaked at $645K in Q4 2017.
1,022 funds tracked by Wall St. Rank held Allergan plc as of Q1 2018.

Based on New Potomac Partners's 13F filing for Q1 2018, filed 18 Apr 2018.